Member Info for TommyD_19

I was talking about the SP as most who know my views on Synairgen would be well aware. Interesting that you post here sativa if that’s your view and particularly as you telling people to get in now!!

Think the shows over

Any sightings?

Guess it was Zero not 1 then ?

The probability that you’re correct is somewhere between zero and 1

Could be CityTraders other buyer who wasn’t going to show their hand until January

Maybe they got stuck at the airport and then couldn’t get a train

Admissions rise by 40% in the last 7 days

I think the phrase used was

Until “at least June 2023”

None of us know how many bidders might be attracted particularly if activ2 develops into a new trial and of course if you bid low and it’s rejected you’re out of the bidding game for a year

I’d be 95% certain Polygon will not be buying this company and any offer for Synairgen cannot be a behind the scenes deal it would be a general offer to all shareholders but I’m sure there would be behind the scenes conversations as to what a 30% shareholder would find acceptable before a bid was made. But don’t expect Polygon to get down on their knees and beg someone to take the shares off their hands. They won’t be in any rush to offload anything if this company has the potential to get an authorised multi virus therapeutic to market

Of course the problem with a JV after p2 was we only had 100 patients, everyone was saying it’s an interesting result but needs a larger trial.

We have no idea what if any JV was available or on what terms at that point

Pump n Dump appears to be over

Looking back

If the company had been a larger Pharma they could have trialled 1500-2000 patients. They would have had the muscle to get first call on those patients in hospitals ahead of many other trials and probably had priority on clinical staff working on multiple trials. They’d have been listened to my regulators and governments.

But they aren’t a large Pharma they’re a tiny company with a handful of employees, so looking back I think they played the best hand they could and the best one they could afford.
The landscape changed with vaccines and treatments. Could they have foreseen it, maybe, but what could they have done about it? Stop vaccinated patients being on the trial, stop patients been given Dexamethesone?

Realistically this tiny company are at the mercy of circumstances beyond their ability to control and have come along way despite the enormous hurdles.

I still believe the company are aiming to maximise value through a JV deal

I doubt any bidder would be on their lonesome. Competition is an interesting game

With only 100 patients approx in the phase 2 data and knowing the reply I received about adhoc analysis. I would caution against raising expectations of Activ data being used towards an EUA. It seems to be highly improbable and the companies focus is clearly on further trials to provide more robust data. Activ2 readout will hopefully lead to a further new trial but that is yet to be defined and drugs selected but we hope to be amongst those candidates chosen

Thanks blue83 and goblesmythe

Can I suggested for clarity of the thread that everyone sticks to a question they would like answered rather than debating the points others have raised.
That way it makes sorting out points of interest easier. Where people have indicated they are attending, I won’t pass on those questions as clearly you’ll be asking them directly. But I appeaciate you mentioning them to help inform other investors.

Thanks manifesto

Thanks HSD